p38 MAPK: A Potential Target of Chronic Pain
p38 MAPK: A Potential Target of Chronic Pain
复制标题
DOI：
10.2174/0929867321666140915143040
复制
发表时间：
2014-01-01
影响因子：
4.1
通讯作者：
Xu, R.
中科院分区：
文献类型：
--
作者：
Lin, X.;Wang, M.;Xu, R.
p38 丝裂原激活蛋白激酶（p38 MAPK、p38）由 4 个亚基组成：p38 α、p38 β、p38 γ 和 p38 δ。它们在调节哺乳动物细胞的细胞内信号转导中发挥着公认的作用。 p38 MAPK 诱导多种与神经性疼痛和其他慢性疼痛相关的细胞内反应。因此，特异性靶向 p38 MAPK 分子及其信号通路代表了疼痛管理的潜在治疗策略。基于对p38 MAPK的晶体结构、生物学功能及其信号通路的了解，化学合成的p38 MAPK抑制剂已成为可能。天然产物和生物成分也可以作为潜在的 p38 MAPK 抑制剂。为此，我们将评估它们在慢性疼痛管理方面的潜力。
p38 mitogen-activated protein kinases (p38 MAPK, p38) consist of 4 subunits: p38 alpha, p38 beta, p38 gamma and p38 delta. They play a well-recognized role in regulating intracellular signaling transduction in mammalian cells. p38 MAPK induces a variety of intracellular responses associated with neuropathic pain and other chronic pain. Thus, specific targeting p38 MAPK molecule and its signaling pathway represent potential therapeutic strategies for pain management. Based on the understanding of the crystal structure, biological functions and its signaling pathway of p38 MAPK, chemically synthesized p38 MAPK inhibitors have become available. Natural products and biological components may also serve as potential p38 MAPK inhibitors. To this end, we will evaluate their potential for chronic pain management.